Amarin (NASDAQ:AMRN – Get Free Report) and Rani Therapeutics (NASDAQ:RANI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.
Profitability
This table compares Amarin and Rani Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amarin | -15.51% | -2.99% | -2.07% |
| Rani Therapeutics | N/A | -206.46% | -83.95% |
Valuation and Earnings
This table compares Amarin and Rani Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amarin | $213.65 million | 1.55 | -$38.80 million | ($0.65) | -24.24 |
| Rani Therapeutics | $1.63 million | 58.90 | -$29.67 million | ($0.41) | -1.89 |
Rani Therapeutics has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Amarin has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Amarin and Rani Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amarin | 2 | 0 | 0 | 1 | 2.00 |
| Rani Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
Amarin presently has a consensus price target of $12.00, indicating a potential downside of 23.83%. Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 1,029.03%. Given Rani Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Amarin.
Institutional & Insider Ownership
22.3% of Amarin shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Rani Therapeutics beats Amarin on 10 of the 15 factors compared between the two stocks.
About Amarin
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
